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Baseline staging tests based on molecular
subtype is necessary for newly diagnosed breast
cancer
Xuesong Chen1†, Lichun Sun1†, Yingying Cong1†, Tingting Zhang2†, Qiushi Lin3, Qingwei Meng1, Hui Pang1,
Yanbin Zhao1, Yu Li4, Li Cai1* and Xiaoqun Dong3*
Abstract
Background: Bone scanning (BS), liver ultrasonography (LUS), and chest radiography (CXR) are commonly
recommended for baseline staging in patients with newly diagnosed breast cancer. The purpose of this study is to
demonstrate whether these tests are indicated for specific patient subpopulation based on clinical staging and
molecular subtype.
Methods: A retrospective study on 5406 patients with newly diagnosed breast cancer was conducted to identify
differences in occurrence of metastasis based on clinical staging and molecular subtypes. All patients had been
evaluated by BS, LUS and CXR at diagnosis.
Results: Complete information on clinical staging was available in 5184 patients. For stage I, II, and III, bone
metastasis rate was 0%, 0.6% and 2.7%, respectively (P < 0.01); liver metastasis rate was 0%, 0.1%, and 1.0%,
respectively (P < 0.01); lung metastasis rate was 0.1%, 0.1%, and 0.7%, respectively (P < 0.01). Complete information
on molecular subtype was available in 3411 patients. For Luminal A, Luminal B (HER2−), Luminal BH (HER2+), HER2+
overexpression, and Basal-like, bone metastasis rate was 1.4%, 0.7%, 2.5%, 2.7%, and 0.9%, respectively (P < 0.05); liver
metastasis rate was 0.1%, 0.1%, 1.0%, 1.1%, and 0.9%, respectively (P < 0.01); lung metastasis rate was 0.20%, 0%, 0%,
0.27%, and 0.9%, respectively (P < 0.05). cT (tumor size), cN (lymph node), PR (progesterone receptor), and HER2
status predicted bone metastasis (P < 0.05). cT, cN, ER (estrogen receptor), PR, and HER2 status predicted liver
metastasis (P < 0.05). cT, cN, and PR status predicted lung metastasis (P < 0.05).
Conclusion: These data indicate that based on clinical staging and molecular subtypes, BS, LUS and CXR are
necessary for patients with newly diagnosed breast cancer.
Keywords: Molecular subtype, Baseline staging, Breast cancer
Introduction
Breast cancer is the most common malignancy in
women in the world and patients are assigned a clinical
stage at diagnosis for efficient local and systemic treat-
ment. It has been shown that detectable metastatic dis-
ease is a low probability event increased with clinical
staging in the newly diagnosed breast cancer [1,2]. Most
common metastatic sites include bone, lung, and liver.
Previous studies proposed unnecessary examinations
without affecting the efficacy of diagnosis and treatment
[3,4], in order to save health expenditure and provide
optimal use of resources.
To better understand molecular pathogenesis of breast
cancer, immunohistochemistry and cDNA microarray have
been used to define major subtypes based on receptor sta-
tus [5,6]. Based on the presence of estrogen receptors (ER),
progesterone receptors (PR) and human epidermal growth
factor receptor 2 (HER2, also known as Neu/ErbB-2),
receptor status along with tumor grading has categorized
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breast cancer into several conceptual molecular classes
[7,8]. The 12th St Gallen International Breast Cancer
Conference (2011) Expert Panel adopted a new approach
to the classification of patients for therapeutic purposes.
Proposed molecular subtypes [9-11] include: 1) Luminal A
[12,13]: ER+ and/or PR+, HER2−, Ki67 < 14%; 2) Luminal B:
ER+ and/or PR+, HER2−, Ki67 ≥ 14%; 3) Luminal BH: ER+
and/or PR+, any Ki67, HER2 overexpressed or amplified; 4)
ERBB2/HER2 overexpression: ER−/PR−, HER2/neu overex-
pressed or amplified; [14] and 5) Basal-like [15]: ER−/
PR−/HER2− (also called triple negative breast cancer,
TNBC; most BRCA1-mutant breast cancers are basal-
like TNBC) [16]. These molecular subtypes are charac-
terized by different epidemiological risk factors, tumor
progression processes, responses to therapy and prog-
nosis [17]. Baseline staging procedures such as bone
scanning (BS), liver ultrasonography (LUS), and chest
radiography (CXR) have been applied in clinical trials
of adjuvant therapy of breast cancer. The current inter-
national guidelines for the management of breast can-
cer are generally against routine use of the above three
examinations to detect asymptomatic distant metasta-
ses in patients with newly diagnosed early-staged breast
cancer [4,18-20]. However, whether specific patient
subpopulation based on clinical staging and molecular
subtype would benefit from the above examinations
needs further investigation. Therefore, the aim of this
study was to determine the frequency and distribution
pattern of metastases categorized by clinical staging
and molecular subtypes in newly diagnosed breast can-
cer patients and to explore the valuable prognosis fac-
tors for bone, liver, and lung metastasis.
Materials and methods
5406 patients with newly diagnosed breast cancer from
January 2000 to July 2010 at Harbin Medical University
Cancer Hospital were included in the current study. The
median age of the patients was 60 (ranging from 18 to
75). 102 patients with bone pain symptoms or elevated
transaminase or alkaline phosphatase and 120 patients
with inadequate information of clinical stage were ex-
cluded, leaving 5184 cases for further analysis. Among
them 3411 cases had completed immunohistochemical
data for subtype classification analysis. All patients were
evaluated by physical examinations to determine their T
(tumor) and N (lymph node) stages. Routine investiga-
tions with BS, LUS and CXR were then carried out to
detect subclinical metastases. Clinical staging was de-
fined by American Joint Committee on Cancer (AJCC)
System [21], based on the current use of subtype cat-
egory [9-11]. Patients suspicious for bone metastases in-
dicated by BS were confirmed by CT or MRI; suspicious
for liver metastases indicated by LUS were confirmed by
live dual phase scan CT; suspicious for lung metastases
indicated by CXR were confirmed by chest CT or MRI.
This retrospective study was approved by the institu-
tional review board at the Third Affiliated Hospital of
Harbin Medical University and conducted according to
all current ethical guidelines.
Statistics
All statistical analysis was conducted by SPSS software
(version 15.0). Differences between categorical variables
in metastatic events were evaluated by chi-square or
Fisher’s exact tests. A p value of <0.05 was considered as
statistically significant.
Results
Metastases were more frequent in bone, than liver and
lung as shown in Table 1 and Figure 1. For stage I, II,
and III, bone metastasis rate was 0%, 0.6% and 2.7%, re-
spectively (P < 0.01); liver metastasis rate was 0%, 0.1%,
1.1%, respectively, (P < 0.01); lung metastasis rate was
0.1%, 0.1%, 0.7%, respectively (P < 0.01).
According to AJCC cT stage (tumor size), for patients
with T1, T2, T3, and T4 disease, bone metastasis rate
was 0.6%, 0.9%, 3.0%, 6.7% respectively (P < 0.01); live
metastasis rate was 0.1%, 0.3%, 0.8%, 2.7%, respectively
(P < 0.01); lung metastasis rate was 0.1%, 0.2%, 0.3%,
2.7%, respectively (P < 0.05).
According to AJCC cN stage (lymph node involve-
ment), for patients with N0, N1, N2, and N3 disease,
bone metastasis rate was 0.2%, 1.2%, 2.1%, and 3.1%, re-
spectively (P < 0.01); liver metastasis rate was 0%,0.2%,
1.0%, and 1.1%, respectively (P < 0.01); lung metastasis rate
was 0.1%, 0.1%, 0.9%, and 0.4%, respectively (P < 0.01).
Complete information on molecular subtype classifica-
tion was available in 3411 patients. For patients defined
as Luminal A, Luminal B, Luminal BH, HER2 overex-
pression, and Basal-like, bone metastasis rate was 1.4%,
0.7%, 2.5%, 2.7%, and 0.9%, respectively (P < 0.05); liver
metastasis rate was 0.1%, 0.1%, 1.0%, 1.1%, and 0.9%, re-
spectively (P < 0.01); lung metastasis rate was 0.2%, 0%,
0%, 0.3%, and 0.9%, respectively (P < 0.05).
Four factors (cT, cN, PR, and HER2) evaluated in the
univariate analysis had significant influences on bone
metastasis (P < 0.05). Five factors (cT, cN, ER, PR, and
HER2) predicted liver metastasis (P < 0.05). Three factors
(cT, cN, and PR) affected lung metastasis (P < 0.05).
Discussion
In this study, we have observed different metastatic rates
derived from molecular subtype classification and identi-
fied the predictors for bone, liver, lung metastasis in
patients with newly diagnosed breast cancer without
symptoms of distant metastases. Our findings suggest
comprehensive BS, LUS and CXR tests are strongly rec-
ommended in those patients at diagnosis.
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Incidence of bone metastasis varies widely in breast
cancer. For patients with stage I, II, and III disease, bone
metastasis rate is ranged from 0.1-6.8%, 0.8-8.8%, and
1.2-24.5% [1,2,4,22,23]. Those studies support that a BS
is necessary for T3N1M0 and stage II/III patients with
skeletal symptoms (such as pain and increased alkaline
phosphatase). Consistently, we did not observe bone me-
tastases in stage I patients. LUS is used to detect liver
metastases, a relatively rare event in early-staged breast
cancer patients. In our patient population, liver metasta-
sis rate was increased with advance in clinical stage (0%,
0.07%, and 1.07% for stage I, II and III). Lung metastasis
rate of stage I, II, and III disease could be ranged from
0–0.1%, 0.2-0.4%, 1.0-4.3%, respectively [2,4,23,24]. Al-
though many anesthesiologists consider CXR as neces-
sary prior to general anesthesia, there is no strong
medical evidence to support that routine CXR is neces-
sary before surgery for breast cancer patients without
symptoms of distant metastases [24-26]. Our data
showed lung metastasis rate of 0.1%, 0.1%, and 0.7% re-
spectively, for patients with stage I, II, and III disease.
Our results support that BS, LUS, and CXR are unneces-
sary for asymptomatic stage I and II patients as routine
examinations.
Biological/pathological behaviors of breast cancer
present race-/time-specificity [27]. For example, there
are significant differences in tumor characteristics be-
tween patients in China and western countries [28]. The
incidence of breast cancer metastasis identified by base-
line staging was inconsistent [24] and very a few studies
on Asian populations had been reported [29]. Undoubt-
edly, breast cancer is a group of heterogeneous diseases
Table 1 Detectable metastatic disease and clinical characteristics of breast cancer patients
Bone metastasis, n (%) Liver metastasis, n (%) Lung metastasis, n (%)
Variables No. of patients (−) (+) P (χ2) (−) (+) P (χ2) (−) (+) P (χ2)
Age (years)
≥ 35 3106 3064 (98.6) 42 (1.4) 1.000 3095 (99.6) 11 (0.4) 0.241 3100 (99.8) 6 (0.2) 0.481
< 35 305 301 (98.7) 4 (1.3) 302 (99.0) 3 (1.0) 304 (99.7) 1 (0.3)
Histological differentiation
I 411 406 (98.8) 5 (1.2) 0.649 409 (99.5) 2 (0.5) 0.95 410 (99.8) 1 (0.2) 0.839
II 2561 2528 (98.7) 33 (1.3) 2551 (99.6) 10 (0.4) 2556 (99.8) 5 (0.2)
III 439 431 (98.2) 8 (1.8) 437 (99.5) 2 (0.5) 438 (99.8) 1 (0.2)
cT stage
cT1 1314 1304 (99.2) 10 (0.8) 0.000 1312 (99.8) 2 (0.2) 0.003 1313 (99.9) 1 (0.1) 0.04
cT2 1859 1833 (98.6) 26 (1.4) 1851 (98.6) 8 (1.4) 1855 (99.8) 4 (0.2)
cT3 198 192 (97.0) 6 (3.0) 196 (98.9) 2 (1.0) 197 (99.5) 1 (0.5)
cT4 40 36 (90.0) 4 (10.0) 38 (95.0) 2 (5.0) 39 (97.5) 1 (2.5)
cN stage
cN0 1592 1588 (99.7) 4 (0.3) 0.000 1592 (100.0) 0 (0.0) 0.000 1591 (99.9) 1 (0.0) 0.018
cN1 1044 1028 (98.5) 16 (1.5) 1042 (99.8) 2 (0.2) 1043 (99.9) 1 (0.2)
cN2 462 449 (97.2) 13 (2.8) 456 (98.7) 6 (1.3) 459 (99.4) 3 (1.3)
cN3 313 300 (95.8) 13 (4.2) 307 (98.1) 6 (1.9) 311 (99.4) 2 (1.9)
ER status
(−) 1317 1301 (98.8) 16 (1.2) 0.591 1307 (99.2) 10 (0.8) 0.011 1312 (99.6) 5 (0.4) 0.162
(+) 2094 2064 (98.6) 30 (1.4) 2090 (99.8) 4 (0.2) 2092 (99.9) 2 (0.1)
PR status
(−) 1131 1110 (98.4) 21 (1.6) 0.07 1122 (99.2) 9 (0.8) 0.028 1126 (99.6) 5 (0.8) 0.08
(+) 2280 2255 (98.8) 25 (1.2) 2275 (99.8) 5 (0.2) 2278 (99.9) 2 (0.1)
HER2 status
(−) 2640 2614 (99.0) 26 (1.0) 0.001 2634 (99.8) 6 (0.2) 0.006 2634 (99.8) 6 (0.2) 0.941
(+) 771 751 (97.4) 20 (2.6) 763 (99.0) 8 (0.1) 770 (99.9) 1 (0.1)
Ki67 index
≤ 14% 1331 1315 (98.8) 16 (0.2) 0.553 1325 (99.5) 6 (0.5) 0.768 1329 (98.8) 2 (1.2) 0.857
> 14% 2080 2050 (98.6) 30 (0.4) 2072 (99.6) 8 (0.4) 2075 (98.6) 5 (1.4)
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with substantial variation in both molecular and clinical
characteristics. Rapid progress has been made in under-
standing the diversity of breast cancer, leading to a new
molecular-driven integrated classification of breast can-
cer. The novel classification integrates molecular and
clinical landscapes of breast cancer to define 5 clusters
with distinct clinical outcomes and provide new insights
into the management of the disease. Our findings have
implications both for the individualization of therapy,
bringing us a step closer to the realization of personal-
ized medicine in breast cancer, but also provide a new
evidence for exploring the underlying mechanisms of
molecular subtypes [30].
Molecular subtype classification is a breakthrough in
breast cancer research [9-11]. Different subtypes have
different epidemiological risk factors, natural histories,
and responses to treatment, which means that clinicians
should consider distinct subtypes before selecting appro-
priate therapeutic strategies. Baseline staging tests after a
new diagnosis of breast cancer based on subtype classifi-
cation are debated. In our study, 3411 patients grouped
into different subtypes showed different rates of bone,
liver and lung metastasis. We also identified predictors
for bone, liver and lung metastases such as cT, cN, ER,
PR and HER2. Although these are not independent
prognostic indicators, they are jointly determined the
distribution of metastatic disease and can be used to
refer to the baseline examination. The data indicate that
patients with stage I breast cancer do not benefit from
radiological staging for the detection of metastatic dis-
ease [18-20]. Preoperative BS, LUS and CXR should be
considered for all of the stage III patients. For stage II
patients, preoperative BS for Luminal BH, HER2 overex-
pression and Basal-like; preoperative LUS for Luminal
BH, HER2 overexpression, and Basal-like; and CXR for
Basal-like subtypes should be considered for early detec-
tion of distant metastases.
The five major molecular subtypes in breast cancer are
different with regard to their ability to metastasize to
distant organ(s), and share biological features and path-
ways with their preferred distant metastatic sites [31].
Previous studies of metastatic sites used postoperative
follow-up data but we used the pre-treatment data in
this study [32,33], which more accurately reflect the nat-
ural history of breast cancer, as well as the distribution
and characteristics of metastatic sites in different sub-
types without interference of treatments. Interestingly,
our pattern of metastatic sites consistent with postopera-
tive follow-up data, suggesting that metastases sites of
breast cancer are dominated by the molecular subtypes
[34], and less affected by treatments. Recent studies have
found that molecular subtypes of breast cancer will
change at relapse [35,36], while whether molecular sub-
types modify the metastatic pattern should be explored
in future. This retrospective study involves a large sam-
ple size compared with previous studies and investigates
Figure 1 Frequency and distribution pattern of detectable metastatic diseases in bone, lung, and liver based on (A) clinical, (B) cT,
(C) cN staging or (D) molecular subtypes. *P < 0.05, **P < 0.01, ***P < 0.001.
Chen et al. Journal of Experimental & Clinical Cancer Research 2014, 33:28 Page 4 of 6
http://www.jeccr.com/content/33/1/28
potential predictors for bone, liver, and lung metastasis
of newly diagnosed asymptomatic breast cancer. The
limitation is that all the clinicopathological variables
were evaluated only by univariate models, due to inad-
equate of positive cases.
Conclusions
In summary, rates of bone, liver, and lung metastasis
showed significant differences between different sub-
types of newly diagnosed breast cancer patients. Baseline
staging tests BS, LUS and CXR after a new diagnosis of
asymptomatic breast cancer are necessary based on sub-
type classification to avoid over– and under-treatment.
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